Selective blocking of spontaneously-active dopamine neurones in ventral tegmental area
CA 2014208 C · Owner: Perregaard Jens · Inventors: Skarsfeldt, Torben; Perregaard Jens
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Psychoses in human beings is treated by administering an effective amount of the compound 5-chloro-1-(4fluorophenyl)-3-(1-(2-(2-imidazolidinon-1-yl)ethyl)-4piperidyl)-lH-indole, or a pharmaceutically acceptable salt thereof, to a patient in need thereof the, compound selectively blocks dopamine neurones in the ventral teqmental area of the brain, substantially without blocking the dopamine neurones in the substantia niqra pars compacta and, therefore is free, from the extrapyramidal side effects of common neuroleptics.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed April 9, 1990 and granted March 19, 1996. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended April 9, 2010.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by April 9, 2012.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.